Skip to main content

Houston Primed for Life Sciences Boom

Published Nov 17, 2022 by A.J. Mistretta

Texas Medical Center Drone Shot

HOUSTON (November 17, 2022) – The Greater Houston Partnership commissioned Newmark Consulting Group to conduct a study, sponsored by San Jacinto College, Lone Star College, Houston Community College, and McCord Development, focused on assessing the Houston region’s existing resources and value proposition in the life sciences industry. 

Findings identified Houston’s industry-leading expertise in cell and gene therapy, biologic drug development, and molecular diagnostics; a continuous flow of new talent from regional universities; an emerging and robust commitment by community colleges to support two-year degree pathways to meet industry demands and the ability for life science companies to grow and thrive in the market. The study also identified strategic next steps for the Houston region to capitalize on these advantages. 

“The Newmark study confirms what we knew to be true about the potential for life sciences growth in Houston,” said Susan Davenport, Chief Economic Development Officer of the Greater Houston Partnership. “The study will help us coalesce our regional partners around a cohesive strategy to grow and expand the industry in Houston.”

Home to nearly 700 life science companies, Houston consistently ranks as a top-15 market for life sciences employment nationwide and first in Texas. Houston benefits from the densest patient population in the world, allowing for transformational clinical applications. With Houston’s robust and diverse workforce, an extensive university ecosystem and education infrastructure, along with world class research institutions, Houston is primed to capture extensive subsector gains. 

Houston ranks second in the nation in clinical trial volume, with more than 4,600 currently active clinical trials, representing 15% of all active U.S. trials. Houston-area institutions received $864.1 million in National Institutes of Health (NIH) grant funding, up 16.3% from 2020. In the last five years, the region received nearly $3.9 billion in NIH funding, an average of $740.7 million per year. Supported by the world-class institutions that comprise the Texas Medical Center and Houston’s sizeable patient population, expansive opportunities exist for commercial synergies with leading healthcare providers in the region. 

As a hub for translational and clinical research and pharmaceutical and medical device manufacturing, Houston is home to more than 26,000 non-healthcare life science employees. Houston’s robust life sciences workforce ranks 12th in the nation, on par with numbers reported for Research Triangle Park. Additionally, Houston compares favorably given its central U.S. location, ample space available and under construction throughout the region, a business friendly environment including accelerated development timelines, and the logistics benefits of  two international airports and the Port of Houston. 

The study finds Houston has the elements necessary to attract key subsectors of the life sciences industry, particularly in cell and gene therapy manufacturing; molecular diagnostics; and biologics drug development and manufacturing.

The study also identifies specific strategies to optimize the region’s “go-to-market” plan to attract more companies in this highly competitive industry.  

These recommendations include accelerating workforce development programs to produce new graduates in key life sciences occupations, refining Houston’s marketing messages to highlight the region’s existing life sciences” assets and activities within life science R&D and manufacturing.  Finally, the study identified the need to develop a shared regional strategy to attract and retain leading life sciences companies. 

The Partnership has assembled task forces to implement the recommendations, which will be led by the organization’s Life Sciences Committee, chaired by Ferran Prat, Senior Vice President of Industry Relations and Research at MD Anderson Cancer Center.

###

Greater Houston Partnership
The Greater Houston Partnership works to make Houston one of the best places to live, work and build a business. As the economic development organization for the region, the Partnership champions growth across 12 counties by bringing together business and civic-minded leaders who are dedicated to the area’s long-term success. Representing 950 member organizations and approximately one-fifth of the region’s workforce, the Partnership is the place companies come together to make an impact. Learn more at Houston.org.

Contact: 
A.J. Mistretta
amistretta@houston.org 
504-450-3516

Related News

Life Sciences

MD Anderson, Rice University Launch New Collaborative to Advance Cancer Research

7/2/24
A new collaboration between The University of Texas MD Anderson Cancer Center and Rice University promises to drive industry growth and advance life-saving technologies through the newly established Cancer Bioengineering Collaborative. The initiative will help foster collaboration between the two institutions on fundamental and translational cancer research, develop new technologies for cancer detection and therapy, and secure external funding in support of further research and training. Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem will lead the hub.  “From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, said in a release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.” The collaborative will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering. Five research areas will be at the core of the hub’s work: Cell therapies: Developing more effective cell-based immunotherapies, including chimeric antigen receptor- and T cell receptor-based approaches. Nanotechnologies: Using nanoparticles for targeted cancer detection and therapy. Cancer vaccines: Incorporating advanced biomaterials, synthetic biology and nanoparticle delivery systems to develop therapeutic cancer vaccines. Artificial intelligence: Leveraging advanced computing tools for high-precision analysis of samples to identify new targets and inform therapeutic design. Molecular imaging: Deploying advanced molecular imaging techniques to enhance diagnostic and therapeutic tools. A seed grant program will also be established to fund research projects in the early stages of development. The partnership between Rice and MD Anderson is a testament to how the greater Houston region is committed to advancing the life sciences and biotech industry. The region has seen major new life science developments come online recently, including Levit Green, TMC Helix Park and The Alexandria Center for Advanced Technologies in The Woodlands.   
Read More
Life Sciences

The Woodlands Innovation District Aims to Attract Life Sciences Companies

6/28/24
A new district in The Woodlands hopes to expand on the area’s resurgence in life sciences developments.    Post pandemic, life sciences companies have been establishing facilities in The Woodlands, particularly along Research Forest Drive. And now, Developers Howard Hughes and Vitrian are building upon that growth by adding an additional 86.3 acres for future development, aiming to attract more biomanufacturing companies to the area. The duo has dubbed the area The Woodlands Innovation District.  “This joint venture further diversifies the innovative industries that are represented in The Woodlands with the advancement of life science,” said Jim Carman, President of the Houston Region for The Howard Hughes Corporation in a statement. “The Woodlands continues to attract companies from a variety of industries seeking a highly-skilled talent pool, business-friendly environment, and high quality of life for their employees.”  The district joins the area’s cluster of existing life sciences companies, such as Millipore Sigma and VGXI. Cellipont Bioservices, a San Diego-based cell therapy contract development and manufacturing organization, recently opened a 76,000-square-foot facility in the area. The facility is dedicated to cell therapies and serves as the company's new headquarters.  Cellipont’s move to the greater Houston region, announced in 2022, kickstarted a surge in life sciences activity in The Woodlands. Bionova Scientific, another California-based biotech company, recently announced plans to expand into the area, with a 100,000-square-foot manufacturing and research facility. The company, which produces materials used by cancer-fighting cell therapy companies, is expected to begin operations at the new location in 2025.  Nearby, Nurix Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco, has relocated to the Alexandria Center for Advanced Technologies. This 12-acre life sciences campus, formerly the Lexicon Pharmaceuticals site, was inaugurated last year with support from Lexicon’s Founder and CEO and now Nurix's Chief Executive Officer, Arthur Sands. Backed by California-based real estate firm Alexandria Real Estate Equities, the campus is still being built out, with the goal of becoming a smaller version of The Texas Medical Center.   These recent developments have established The Woodlands as a leader in life sciences in the region. According to CBRE’s 2023 U.S. Life Sciences Outlook, The Woodlands accounted for 60% of the Houston region’s life sciences lease transactions in 2022.  The Woodlands Innovation District will encompass five sites, each providing tenant facilities ranging from 40,000 to over 200,000 square feet. These sites will offer build-to-suit shell spaces, anticipated to be move-in ready by Spring 2025.  Learn more about Houston’s life sciences and biotechnology industries. 
Read More

Related Events

Health Care

Life Sciences and Biotechnology Forum

Finding solutions to the problems that matter most is baked into Houston’s DNA. As the Third Coast for Life Sciences, the region’s world-class medical centers, research institutes and private companies are taking on…

Learn More
Learn More
Executive Partners